Champalimaud Research Symposium 2017 -- Physiology: From Development to Disease

March 03, 2017

The 2017 Champalimaud Research Symposium, with the theme "Physiology: from development to disease" will be held in Lisbon, Portugal from the 9th to the 11th of October 2017. The Symposium will be a single-track scientific meeting with 14 invited speakers. It will focus on modern physiology in development, aging, immunity and cancer, bridging cutting edge biology research with disease oriented research, and will feature a keynote lecture from Professor Bob Horvitz, winner of the 2002 Prize in Physiology or Medicine, shared with Sydney Brenner and John Sulston, "for their discoveries concerning genetic regulation of organ development and programmed cell death".

This Symposium is a very special event as it will serve as the inaugural conference to launch the Champalimaud Biology of Systems and Metastasis Research Program. This new research program, together with the neuroscience program, aims at establishing the Champalimaud Centre for the Unknown as a premier biomedical research effort. After five successful neuroscience symposia, it is a great pleasure to commence this new phase of the Champalimaud Research with what promises to be this exciting and rewarding Symposium. The diverse list of distinguished speakers shown below will reflect the vision for our research.

The Symposium will be held at our Centre on the stunning waterfront in Lisbon, and will also feature a social programme which will give participants the chance to explore this beautiful and historic city. We expect that the unique venue, together with the exciting list of invited speakers, will foster a lively and stimulating scientific meeting.
-end-


Champalimaud Centre for the Unknown

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.